Umbralisib, ublituximab and venetoclax in patients with relapsed or refractory c...
Dr Paul Barr - Wilmot Cancer Institute, University of Rochester Medical Center
Umbralisib, ublituximab and venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia ( Dr Paul Barr - Wilmot Cancer Institute, University of Rochester Medical Center )
17 Dec 2019
GLS1 dependency in MYC over-expressing multiple myeloma: New target for therapy?
Dr Salomon Manier - Dana-Farber Cancer Institute, Boston, USA
GLS1 dependency in MYC over-expressing multiple myeloma: New target for therapy? ( Dr Salomon Manier - Dana-Farber Cancer Institute, Boston, USA )
17 Dec 2019
Predicting early relapse in transplant-eligible MM patients using baseline progn...
Dr Francesca Gay - University of Torino, Torino, Italy
Predicting early relapse in transplant-eligible MM patients using baseline prognostic features and MRD negativity ( Dr Francesca Gay - University of Torino, Torino, Italy )
17 Dec 2019
Using multiparameter flow cytometry and next generation sequencing to evaluate M...
Dr Francesca Gay - University of Torino, Torino, Italy
Using multiparameter flow cytometry and next generation sequencing to evaluate MRD in NDMM patients from the FORTE trial ( Dr Francesca Gay - University of Torino, Torino, Italy )
17 Dec 2019
Complete remission after induction chemotherapy determines clinical efficacy of ...
Prof Kristoffer Hellstrand - University of Gothenburg, Gothenburg, Sweden
Complete remission after induction chemotherapy determines clinical efficacy of relapse-preventive immunotherapy in AML ( Prof Kristoffer Hellstrand - University of Gothenburg, Gothenburg, Sweden )
17 Dec 2019
FiTNEss: Investigating frailty-adjusted therapy in transplant non-eligible patie...
Prof David Cairns - University of Leeds, Leeds, UK
FiTNEss: Investigating frailty-adjusted therapy in transplant non-eligible patients with NDMM ( Prof David Cairns - University of Leeds, Leeds, UK )
17 Dec 2019
Myeloma highlights from ASH 2019
Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA
Myeloma highlights from ASH 2019 ( Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA )
13 Dec 2019
Weekly wKRd-D in newly diagnosed multiple myeloma achieves unprecedented results
Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA
Weekly wKRd-D in newly diagnosed multiple myeloma achieves unprecedented results ( Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA )
13 Dec 2019
Chronic lymphocytic leukaemia highlights from ASH 2019
Dr John Seymour - Peter MacCallum Cancer Centre, Melbourne, Australia
Chronic lymphocytic leukaemia highlights from ASH 2019 ( Dr John Seymour - Peter MacCallum Cancer Centre, Melbourne, Australia )
13 Dec 2019
Benefits of apixaban among venous thromboembolism patients with active cancer
Dr Alexander Cohen - Guys and St Thomas, London, UK
Benefits of apixaban among venous thromboembolism patients with active cancer ( Dr Alexander Cohen - Guys and St Thomas, London, UK )
13 Dec 2019
Inotuzumab ozogamicin and chemotherapy with or without blinatumomab in Philadelp...
Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA
Inotuzumab ozogamicin and chemotherapy with or without blinatumomab in Philadelphia chromosone-negative ALL ( Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA )
13 Dec 2019
Dasatinib vs imatinib for paediatric Ph ALL
Dr Ching-Hon Pui - St Jude's Children's Research Hospital, Memphis, USA
Dasatinib vs imatinib for paediatric Ph ALL ( Dr Ching-Hon Pui - St Jude's Children's Research Hospital, Memphis, USA )
12 Dec 2019